- Home
- APPF vs RGEN Comparison
APPF vs RGEN Comparison
Compare APPF & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPF
- RGEN
- Stock Information
- Founded
- APPF 2006
- RGEN 1981
- Country
- APPF United States
- RGEN United States
- Employees
- APPF N/A
- RGEN N/A
- Industry
- APPF Computer Software: Prepackaged Software
- RGEN Medical/Dental Instruments
- Sector
- APPF Technology
- RGEN Health Care
- Exchange
- APPF Nasdaq
- RGEN Nasdaq
- Market Cap
- APPF 7.9B
- RGEN 8.0B
- IPO Year
- APPF 2015
- RGEN N/A
- Fundamental
- Price
- APPF $218.91
- RGEN $126.50
- Analyst Decision
- APPF Buy
- RGEN Buy
- Analyst Count
- APPF 6
- RGEN 12
- Target Price
- APPF $271.20
- RGEN $172.67
- AVG Volume (30 Days)
- APPF 376.8K
- RGEN 815.5K
- Earning Date
- APPF 04-24-2025
- RGEN 04-29-2025
- Dividend Yield
- APPF N/A
- RGEN N/A
- EPS Growth
- APPF 158.56
- RGEN N/A
- EPS
- APPF 5.36
- RGEN N/A
- Revenue
- APPF $824,474,000.00
- RGEN $650,429,000.00
- Revenue This Year
- APPF $20.11
- RGEN $13.93
- Revenue Next Year
- APPF $16.68
- RGEN $14.35
- P/E Ratio
- APPF $40.97
- RGEN N/A
- Revenue Growth
- APPF 22.73
- RGEN 4.88
- 52 Week Low
- APPF $189.01
- RGEN $102.97
- 52 Week High
- APPF $274.56
- RGEN $182.52
- Technical
- Relative Strength Index (RSI)
- APPF 52.76
- RGEN 44.61
- Support Level
- APPF $209.24
- RGEN $123.10
- Resistance Level
- APPF $222.34
- RGEN $135.47
- Average True Range (ATR)
- APPF 5.74
- RGEN 6.98
- MACD
- APPF 0.76
- RGEN -0.97
- Stochastic Oscillator
- APPF 85.49
- RGEN 25.20
About APPF AppFolio Inc.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.